This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Dynavax May Seek Quick Re-File of HepB Vax Following FDA Rejection

Stocks in this article: DVAX

BERKELEY, Calif. ( TheStreet) -- The U.S. Food and Drug Administration rejected Dynavax's (DVAX) hepatitis B vaccine Heplisav, citing the need for additional safety data in healthy adults.

Dynavax shares fell 37% to $1.88 in Monday's pre-market session because that's what happens to companies who fail to get their first product to market on time. The stock closed Friday at $2.97

How long Dynavax will need to wait before re-filing Heplisav isn't clear but the company may not be delayed too long if it decides to seek approval first in a sicker patient population. "The Agency indicated its willingness to continue discussions regarding a more restricted use of Heplisav," Dynavax said in its Monday statement.

That restricted patient population could be people with chronic kidney disease. Dynavax was already planning to submit additional Heplisav data on this patient population as a post-approval supplement.

Dynavax might be able to re-file Heplisav in chronic kidney disease patients by the middle of this year, with approval and commercial launch in the middle of 2014, said Jefferies analyst Thomas Wei in a research note issued last Thursday. A broader label for Heplisav could be approved in 2015, he added.

Dynavax plans to meet with FDA within six weeks to discuss options.

In rejected Heplisav, FDA concurred with the recommendation of an advisory panel, which voted against the vaccine because of concerns about the lack of safety data in a broad population of healthy adults aged 18-70.

The FDA's rejection letter also asked Dynavax to provide additional information related to Heplisav's manufacturing.

"We had the chance to speak with the company, and it noted that there are essentially two options at the moment 1) run an additional safety study in patients aged 18-70 years, or 2) move forward with a more restrictive label (CKD or >40 years of age)," writes J.P. Morgan analyst Geoff Meacham in a research note issued Monday morning. "Of note, the request for manufacturing data comes as somewhat of a surprise, but the company is confident it can provide the requested information."

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs